We are live on ! Find out more
NVS icon

Novartis

877 hedge funds and large institutions have $18.7B invested in Novartis in 2016 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 324 increasing their positions, 338 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 44

11% more call options, than puts

Call options by funds: $50M | Put options by funds: $45M

0.05% more ownership

Funds ownership: 9.98%10.03% (+0.05%)

0% less funds holding

Funds holding: 879877 (-2)

4% less capital invested

Capital invested by funds: $19.4B → $18.7B (-$719M)

4% less repeat investments, than reductions

Existing positions increased: 324 | Existing positions reduced: 338

24% less funds holding in top 10

Funds holding in top 10: 3728 (-9)

Holders
877
Holders Change
-2
Holders Change %
-0.23%
% of All Funds
23.33%
Holding in Top 10
28
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-24.32%
% of All Funds
0.74%
New
53
Increased
324
Reduced
338
Closed
44
Calls
$50M
Puts
$45M
Net Calls
+$5M
Net Calls Change
+$2.72M

NVS Hedge Fund Activity: Q3 2016 in Review

877 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2016, worth a combined $18.7B — down 3.7% from $19.4B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new NVS positions and 44 closed out — a net gain of 9 holders — while 324 added to existing stakes and 338 trimmed.

The largest buyer was Parnassus Investments, adding an estimated $64.7M. The largest seller was JP Morgan Chase, cutting an estimated $72.6M.

  • 877 institutional investors held Novartis (NVS) as of Q3 2016, down from 879 in Q2 2016.
  • Funds reported $18.7B of Novartis stock for Q3 2016, down 3.7% quarter-over-quarter.
  • 53 funds opened new Novartis positions in Q3 2016 and 44 closed out, a net change of +9 holders.
  • The largest Novartis buyer in Q3 2016 was Parnassus Investments, an estimated $64.7M added.
  • The largest Novartis seller in Q3 2016 was JP Morgan Chase, an estimated $72.6M sold.

Based on aggregated 13F filings for Q3 2016.